ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up- regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity

Laura L. Worth, Shu Fang Jia, Taeha An, Eugenie S. Kleinerman

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

ImmTher, a liposome-encapsulated lipophilic disaccharide tripeptide derivative of muramyl dipeptide, previously showed activity against liver and lung colorectal metastases in a phase I trial. The purpose of the current studies was to investigate whether ImmTher could up-regulate specific cytokine gene expression and protein production, as well as activate the tumoricidal or cytostatic activity of human monocytes. ImmTher induced the expression and production of interleukin(IL)-1α IL-1β, IL-6, IL-8, IL-12, macrophage chemotactic and activating factor, and tumor necrosis factor α but not IL-2 or IL-10. Cytostatic or cytotoxic monocyte activity was stimulated against human Ewing's sarcoma, osteosarcoma, and melanoma cells but not breast cancer cells. Production and secretion of these cytokine proteins may play a role in the antitumor activity of ImmTher.

Original languageEnglish (US)
Pages (from-to)312-320
Number of pages9
JournalCancer Immunology Immunotherapy
Volume48
Issue number6
DOIs
StatePublished - 1999

Keywords

  • Cytokine activation
  • ImmTher
  • Immunotherapy
  • Liposome- encapsulated
  • Macrophage cytotoxicity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up- regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity'. Together they form a unique fingerprint.

Cite this